Protara Therapeutics, Inc. (TARA) — Financial statements
Income statement, balance sheet, and cash flow for Protara Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.36 | 0.00↓100.0% | 0.34 | 0.00 | 0.00 | |
| Gross Profit | -0.36 | 0.00↑100.0% | -0.34 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 43↑34.5% | 32↑27.9% | 25↑47.5% | 17↓20.3% | 21 | |
| General & Administrative Expenses | 22↑25.6% | 17↓6.3% | 19↓10.2% | 21↓21.5% | 26 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 22↑25.6% | 17↓6.3% | 19↓10.2% | 21↓21.5% | 26 | |
| Other Expenses | -0.36 | 0.00↑100.0% | -0.14↓100.5% | 30 | 0.00 | |
| Operating Expenses | 64↑30.6% | 49↑13.6% | 43↓35.5% | 67↑41.2% | 47 | |
| Total Costs & Expenses | 65↑31.3% | 49↑12.7% | 44↓35.0% | 67↑41.2% | 47 | |
| Operating Results | ||||||
| Operating Income | -65↓31.3% | -49↓12.7% | -44↑35.0% | -67↓41.2% | -47 | |
| Depreciation & Amortization | 0.36↑9.0% | 0.33↓2.6% | 0.34↑37.5% | 0.25↑112.0% | 0.12 | |
| EBITDA | -64↓31.5% | -49↓12.8% | -43↑33.0% | -65↓42.2% | -45 | |
| EBIT | -65↓31.3% | -49↓12.7% | -44↑32.7% | -65↓42.4% | -46 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↑53.1% | 4↑51.6% | 3↑10200.0% | -0.03↑98.2% | -2 | |
| Interest Income | 6↑53.1% | 4↑51.6% | 3↑145.7% | 1↑368.4% | 0.24 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 1↓34.5% | 2 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↑100.0% | -2↓13.8% | -2 | |
| Other Income / Expenses | 7↑56.0% | 5↑42.7% | 3↑187.7% | 1↑368.4% | 0.24 | |
| Income Before Tax | -57↓28.8% | -45↓10.3% | -40↑38.7% | -66↓39.6% | -47 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -57↓28.8% | -45↓10.3% | -40↑38.7% | -66↓39.6% | -47 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -57↓28.8% | -45↓10.3% | -40↑38.7% | -66↓39.6% | -47 | |
| Bottom-Line Net Income | -57↓28.8% | -45↓10.3% | -40↑38.7% | -66↓39.6% | -47 | |
| EPS (Basic) | -1.34↑38.2% | -2.17↑39.2% | -3.57↑39.1% | -5.86↓39.5% | -4.20 | |
| EPS (Diluted) | -1.34↑38.2% | -2.17↑39.2% | -3.57↑39.1% | -5.86↓39.5% | -4.20 | |
| Weighted Average Shares | 43↑108.0% | 21↑81.7% | 11↑0.6% | 11↑0.2% | 11 | |
| Weighted Average Diluted Shares | 43↑108.0% | 21↑81.7% | 11↑0.6% | 11↑0.2% | 11 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.